

March 25, 2015

## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (CD-80) BRONTICTUZUMAB

PRONUNCIATION bron" tik tooz' ue mab

THERAPEUTIC CLAIM Treatment of cancer

## CHEMICAL NAMES

1. Immunoglobulin G2 (human-Mus musculus monoclonal OMP-52M51 heavy chain), disulfide with human-Mus musculus monoclonal OMP-52M51 light chain, dimer
2. Immunoglobulin G2-lambda, anti-[Homo sapiens NOTCH1 (Notch 1, Translocation-associated notch-1, TAN-1, TAN1)], humanized monoclonal antibody; gamma2 heavy chain (1-447) [humanized VH (Homo sapiens IGHV1-24\*01 (80.40%) -(IGHD)-IGHJ4\*01 L123>T (116)) [8.8.14] (1- 121) - Homo sapiens IGHG2\*01 (CH1 (122-219), hinge (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)],(135- 214')-disulfide with lambda light chain (1'-215') [humanized V-LAMBDA (Homo sapiens IGLV7-46\*01 (83.20%) -IGLJ2\*01) [9.3.9] (1'-109') -Homo sapiens IGLC7\*01 (110'-215')]; dimer (223- 223":224-224":227-227":230-230")-tetrakisdisulfide

## STRUCTURAL FORMULA

## Heavy chain

QVQLVQSGAE	VKKPGASVKI	SCKVSGYTLR	GYWIEWVRQA	PGKGLEWIGQ	50
ILPGTGRITNY	NEKFKGRVTM	TADTSTDITAY	MELSSLRSED	TAVYYCARFD	100
GNVGYIAMDY	WGQGTITVTVS	SASTKGPSVF	PLAPCSRSTS	ESTAALGCLV	150
KDYFPEPVTV	SWNSGALTS	VHTFPAVLQS	SGLYSLSSVV	TVPSNFGTQ	200
TYTCNVDHKP	SNTKVDKTE	RKCCVECPPC	PAPPVAGPSV	FLFPPKPKDT	250
LMISRTPEVT	CVVVDVSHED	PEVQFNWYVD	GVEVHNAKTK	PREEQFNSTF	300
RVVSVLTIVVH	QDWLNGKEYK	CKVSNKGLPA	PIEKTISKTK	GQPREPQVYT	350
LPPSREEMTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	YKTTTPMLDS	400
DGSFFLYSKL	TVDKSRWQQG	NVFSQSVMHE	ALHNHYTQKS	LSLSPGK	447

## Light chain

QAVVTQEPSSL	TVSPGGTVTL	TCRSSTGAVT	TSNYANWFQQ	KPGQAPRTLI	50'
GGTNNRAPGV	PARFSGSLLG	GKAALTLSGA	QPEDEAEYYC	ALWYNSHWVF	100'
GGGTKLTVLG	QPKAAPSVTL	FPPSSEELQA	NKATLVCLVS	DFYPGAVTVA	150'
WKADGSPVKV	GVETTKPSKQ	SNNKYAASSY	LSLTPEQWKS	HRSYSCRVT	200'
EGSTVEKTVA	PAECS				215'

## Disulfide bridges location

22-96	22''-96''	22'-90'	22'''-90'''	135-214'	135'''-214'''	137'-196'	137'''-196'''
148-204	148'''-204'''	223-223''	224-224''	227-227''	230-230''	261-321	261'''-321'''
367-425	367''-425''						

Glycosylation sites (N)

Asn-297 Asn-297 "

MOLECULAR FORMULA	$C_{6392}H_{9862}O_{1980}N_{1710}S_{50}$
MOLECULAR WEIGHT	143.9 kDA
TRADEMARK	None as yet
SPONSOR	OncoMed Pharmaceuticals
CODE DESIGNATIONS	OMP-52M51
<u>CAS</u> REGISTRY NUMBER	1447814-75-6
UNII	UNY2TQA40E
WHO NUMBER	9982

gbk